TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B

Thermo Fisher Scientific total debt 1985–2026

Thermo Fisher Scientific's total debt was 41.37B USD on 26 September 2026, up 15.9% on a year before. At the end of fiscal year 2025 it was 39.39B USD.

Last updated 3 Nov 2026 · Next report 4 Feb 2027

Total debt

Growth

Fiscal yearPeriod endingTotal debtGrowthCash and short-term investmentsNet cashDebt to equity
Latest quarter26 Sept 202641.37B+15.95%6.06B-35.31B0.76
FY202531 Dec 202539.39B+20.17%10.11B-29.28B0.74
FY202431 Dec 202432.78B-10.02%5.58B-27.20B0.66
FY202331 Dec 202336.42B+0.97%8.08B-28.34B0.78
FY202231 Dec 202236.07B-0.73%8.52B-27.55B0.82
FY202131 Dec 202136.34B+61.18%4.48B-31.86B0.89
FY202031 Dec 202022.55B+21.93%10.33B-12.22B0.65
FY201931 Dec 201918.49B-2.63%2.40B-16.09B0.62
FY201831 Dec 201818.99B-9.61%2.10B-16.89B0.69
FY201731 Dec 201721.01B+26.34%1.34B-19.67B0.83
FY201631 Dec 201616.63B+33.32%786.00M-15.84B0.77
FY201531 Dec 201512.47B-14.36%452.10M-12.02B0.58
FY201431 Dec 201414.56B+38.87%1.34B-13.22B0.71
FY201331 Dec 201310.49B+47.20%5.83B-4.65B0.62
FY201231 Dec 20127.12B+1.37%809.90M-6.31B0.46
FY201131 Dec 20117.03B+223.81%1.02B-6.01B0.47
FY201031 Dec 20102.17B-0.60%926.00M-1.24B0.14
FY200931 Dec 20092.18B+6.08%1.57B-612.20M0.14
FY200831 Dec 20082.06B-6.24%1.29B-770.30M0.14
FY200731 Dec 20072.20B-17.60%639.20M-1.56B0.15
FY200631 Dec 20062.66B+344.91%715.60M-1.95B0.19
FY200531 Dec 2005598.77M+148.36%294.99M-303.78M0.21
FY200431 Dec 2004241.09M-12.49%512.26M271.17M0.09
FY200331 Dec 2003275.49M-70.56%418.24M142.75M0.12
FY200231 Dec 2002935.82M+18.91%875.47M-60.35M0.46
FY200131 Dec 2001787.00M-51.09%1.04B255.00M0.41
FY200031 Dec 20001.61B-4.17%1.03B-582.00M0.63
FY199931 Dec 19991.68B-22.27%838.00M-841.00M0.83
FY199831 Dec 19982.16B+12.50%1.55B-612.00M0.96
FY199731 Dec 19971.92B+12.68%1.52B-397.00M0.96
FY199631 Dec 19961.70B+39.44%1.85B142.00M0.97
FY199531 Dec 19951.22B+7.87%1.06B-166.00M0.94
FY199431 Dec 19941.13B+63.37%382.80M-750.00M1.14
FY199331 Dec 1993693.40M+34.33%325.70M-367.70M0.79
FY199231 Dec 1992516.20M+98.61%190.60M-325.60M0.92
FY199131 Dec 1991259.90M+19.88%131.00M-128.90M0.53
FY199031 Dec 1990216.80M+8.62%117.90M-98.90M0.69
FY198931 Dec 1989199.60M+24.91%93.90M-105.70M0.95
FY198831 Dec 1988159.80M+13.33%136.40M-23.40M0.88
FY198731 Dec 1987141.00M+124.17%144.10M3.10M0.87
FY198631 Dec 198662.90M+23.33%63.80M900.00K0.43
FY198531 Dec 198551.00M—30.00M-21.00M0.50

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Total debt counts commercial paper, term debt and lease liabilities.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Free cash flow,Stock buybacks,Balance sheet

Common questions about Thermo Fisher Scientific's debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.